相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。ARISE: A Phase 3 randomized trial of erenumab for episodic migraine
David W. Dodick et al.
CEPHALALGIA (2018)
A multicenter, prospective, single arm, open label, observational study of sTMS for migraine prevention (ESPOUSE Study)
Amaal J. Starling et al.
CEPHALALGIA (2018)
Headache Classification Committee of the International Headache Society (IHS) The International Classification of Headache Disorders, 3rd edition
Jes Olesen
CEPHALALGIA (2018)
Non-Pharmacological Approaches for Migraine
Francesca Puledda et al.
NEUROTHERAPEUTICS (2018)
Evaluation of Galcanezumab for the Prevention of Episodic Migraine The EVOLVE-1 Randomized Clinical Trial
Virginia L. Stauffer et al.
JAMA NEUROLOGY (2018)
Effect of Different Doses of Galcanezumab vs Placebo for Episodic Migraine Prevention A Randomized Clinical Trial
Vladimir Skljarevski et al.
JAMA NEUROLOGY (2018)
The safety and efficacy of the 5-HT 1F receptor agonist lasmiditan in the acute treatment of migraine
Bianca Raffaelli et al.
EXPERT OPINION ON PHARMACOTHERAPY (2017)
Psychometric Evaluation of a Novel Instrument Assessing the Impact of Migraine on Physical Functioning: The Migraine Physical Function Impact Diary
Ariane K. Kawata et al.
HEADACHE (2017)
Fremanezumab as Add-On Treatment for Patients Treated With Other Migraine Preventive Medicines
Joshua M. Cohen et al.
HEADACHE (2017)
A multicenter, open-label, long-term safety and tolerability study of DFN-02, an intranasal spray of sumatriptan 10 mg plus permeation enhancer DDM, for the acute treatment of episodic migraine
Sagar Munjal et al.
JOURNAL OF HEADACHE AND PAIN (2017)
Randomized, double-blind, crossover study comparing DFN-11 injection (3 mg subcutaneous sumatriptan) with 6 mg subcutaneous sumatriptan for the treatment of rapidly-escalating attacks of episodic migraine
Roger K. Cady et al.
JOURNAL OF HEADACHE AND PAIN (2017)
Fluctuations in episodic and chronic migraine status over the course of 1 year: implications for diagnosis, treatment and clinical trial design
Daniel Serrano et al.
JOURNAL OF HEADACHE AND PAIN (2017)
National Trends in Direct Health Care Expenditures Among US Adults With Migraine: 2004 to 2013
Amit D. Raval et al.
JOURNAL OF PAIN (2017)
Global, regional, and national burden of neurological disorders during 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015
Valery L. Feigin et al.
LANCET NEUROLOGY (2017)
External Trigeminal Nerve Stimulation for the Acute Treatment of Migraine: Open-Label Trial on Safety and Efficacy
Denise E. Chou et al.
NEUROMODULATION (2017)
Fremanezumab for the Preventive Treatment of Chronic Migraine
Stephen D. Silberstein et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
A Controlled Trial of Erenumab for Episodic Migraine
Peter J. Goadsby et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Premonitory symptoms in migraine: A cross-sectional study in 2714 persons
Katarina Laurell et al.
CEPHALALGIA (2016)
A Randomized Trial Comparing the Pharmacokinetics, Safety, and Tolerability of DFN-02, an Intranasal Sumatriptan Spray Containing a Permeation Enhancer, With Intranasal and Subcutaneous Sumatriptan in Healthy Adults
Sagar Munjal et al.
HEADACHE (2016)
Measuring the impact of migraine for evaluating outcomes of preventive treatments for migraine headaches
Sally Mannix et al.
HEALTH AND QUALITY OF LIFE OUTCOMES (2016)
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
Hong Sun et al.
LANCET NEUROLOGY (2016)
Practice guideline update summary: Botulinum neurotoxin for the treatment of blepharospasm, cervical dystonia, adult spasticity, and headache Report of the Guideline Development Subcommittee of the American Academy of Neurology
David M. Simpson et al.
NEUROLOGY (2016)
Drug safety in acute migraine treatment
Janos Tajti et al.
EXPERT OPINION ON DRUG SAFETY (2015)
AVP-825 Breath-Powered Intranasal Delivery System Containing 22mg Sumatriptan Powder vs 100mg Oral Sumatriptan in the Acute Treatment of Migraines (The COMPASS Study): A Comparative Randomized Clinical Trial Across Multiple Attacks
Stewart J. Tepper et al.
HEADACHE (2015)
The Acute Treatment of Migraine in Adults: The American Headache Society Evidence Assessment of Migraine Pharmacotherapies
Michael J. Marmura et al.
HEADACHE (2015)
A pilot study of cognitive behavioural therapy and relaxation for migraine headache: a randomised controlled trial
S. Cousins et al.
JOURNAL OF NEUROLOGY (2015)
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
Marcelo E. Bigal et al.
LANCET NEUROLOGY (2015)
Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of high-frequency episodic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study
Marcelo E. Bigal et al.
LANCET NEUROLOGY (2015)
Ineffective acute treatment of episodic migraine is associated with new-onset chronic migraine
Richard B. Lipton et al.
NEUROLOGY (2015)
Adherence to oral migraine-preventive medications among patients with chronic migraine
Zsolt Hepp et al.
CEPHALALGIA (2015)
A Randomized, Double-Blind, Placebo-Controlled Study of Breath Powered Nasal Delivery of Sumatriptan Powder (AVP-825) in the Treatment of Acute Migraine (The TARGET Study)
Roger K. Cady et al.
HEADACHE (2015)
Systematic review of cognitive behavioural therapy for the management of headaches and migraines in adults
Petra Harris et al.
BRITISH JOURNAL OF PAIN (2015)
Revised French guidelines for the diagnosis and management of migraine in adults and children
Michel Lanteri-Minet et al.
JOURNAL OF HEADACHE AND PAIN (2014)
Safety and efficacy of LY2951742, a monoclonal antibody to calcitonin gene-related peptide, for the prevention of migraine: a phase 2, randomised, double-blind, placebo-controlled study
David W. Dodick et al.
LANCET NEUROLOGY (2014)
Safety and efficacy of ALD403, an antibody to calcitonin gene-related peptide, for the prevention of frequent episodic migraine: a randomised, double-blind, placebo-controlled, exploratory phase 2 trial
David W. Dodick et al.
LANCET NEUROLOGY (2014)
What Do Patients Consider to Be the Most Important Outcomes for Effectiveness Studies on Migraine Treatment? Results of a Delphi Study
Antonia F. H. Smelt et al.
PLOS ONE (2014)
Cutaneous allodynia as a predictor of migraine chronification
Mark A. Louter et al.
BRAIN (2013)
Patterns of Use and Reasons for Discontinuation of Prophylactic Medications for Episodic Migraine and Chronic Migraine: Results From the Second International Burden of Migraine Study (IBMS-II)
Andrew M. Blumenfeld et al.
HEADACHE (2013)
Cutaneous allodynia in patients with episodic migraine
Hayat Guven et al.
NEUROLOGICAL SCIENCES (2013)
Cost and Predictors of Lost Productive Time in Chronic Migraine and Episodic Migraine: Results from the American Migraine Prevalence and Prevention (AMPP) Study
Daniel Serrano et al.
VALUE IN HEALTH (2013)
Validating Migraine-Specific Quality of Life Questionnaire v2.1 in Episodic and Chronic Migraine
Christine L. Bagley et al.
HEADACHE (2012)
Headache Impact of Chronic and Episodic Migraine: Results From the American Migraine Prevalence and Prevention Study
Dawn Buse et al.
HEADACHE (2012)
Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults Report of the Quality Standards Subcommittee of the American Academy of Neurology and the American Headache Society
S. D. Silberstein et al.
NEUROLOGY (2012)
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 1 trial
S. K. Aurora et al.
CEPHALALGIA (2010)
OnabotulinumtoxinA for treatment of chronic migraine: Results from the double-blind, randomized, placebo-controlled phase of the PREEMPT 2 trial
H. C. Diener et al.
CEPHALALGIA (2010)
Biofeedback in headache: An overview of approaches and evidence
F. ANDRASIK
CLEVELAND CLINIC JOURNAL OF MEDICINE (2010)
Effect of preventive (β blocker) treatment, behavioural migraine management, or their combination on outcomes of optimised acute treatment in frequent migraine: randomised controlled trial
Kenneth A. Holroyd et al.
BMJ-BRITISH MEDICAL JOURNAL (2010)
Temporomandibular disorders and cutaneous allodynia are associated in individuals with migraine
D. B. Grossi et al.
CEPHALALGIA (2009)
A Comparison of Migraine Patients With and Without Allodynic Symptoms
Jayantee Kalita et al.
CLINICAL JOURNAL OF PAIN (2009)
Medication overuse headache
Zaza Katsarava et al.
CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS (2009)
EFNS guideline on the drug treatment of migraine - revised report of an EFNS task force
S. Evers et al.
EUROPEAN JOURNAL OF NEUROLOGY (2009)
Economic Burden of Transformed Migraine: Results From the American Migraine Prevalence and Prevention (AMPP) Study
Julie Munakata et al.
HEADACHE (2009)
Cutaneous allodynia in the migraine population
Richard B. Lipton et al.
ANNALS OF NEUROLOGY (2008)
Guidelines for controlled trials of prophylactic treatment of chronic migraine in adults
S. Silberstein et al.
CEPHALALGIA (2008)
Acute migraine medications and evolution from episodic to chronic migraine: A longitudinal population-based study
Marcelo E. Bigal et al.
HEADACHE (2008)
Biofeedback treatment for headache disorders: A comprehensive efficacy review
Yvonne Nestoriuc et al.
APPLIED PSYCHOPHYSIOLOGY AND BIOFEEDBACK (2008)
The impact of topiramate on health-related quality of life indicators in chronic migraine
David W. Dodick et al.
HEADACHE (2007)
Efficacy of eletriptan in migraine-related functional impairment: Functional and work productivity outcomes
Stephen D. Silberstein et al.
HEADACHE (2007)
Pharmacological approaches to managing migraine and associated comorbidities - Clinical considerations for monotherapy versus polytherapy
Stephen D. Silberstein et al.
HEADACHE (2007)
Migraine prevalence, disease burden, and the need for preventive therapy
R. B. Lipton et al.
NEUROLOGY (2007)
Acute migraine treatment: Patterns of use and satisfaction in a clinical population
SN Malik et al.
HEADACHE (2006)
Four methods of estimating the minimal important difference score were compared to establish a clinically significant change in Headache Impact Test
RR Coeytaux et al.
JOURNAL OF CLINICAL EPIDEMIOLOGY (2006)
Validation of the revised patient perception of migraine questionnaire: Measuring satisfaction with acute migraine treatment
DA Revicki et al.
HEADACHE (2006)
Identifying patients who require a change in their current acute migraine treatment: the Migraine Assessment of Current Therapy (Migraine-ACT) questionnaire
AJ Dowson et al.
CURRENT MEDICAL RESEARCH AND OPINION (2004)
Prevalence and burden of migraine in the United States: Data from the American Migraine Study II
RB Lipton et al.
HEADACHE (2001)
Development and testing of the Migraine Disability Assessment (MIDAS) Questionnaire to assess headache-related disability
WF Stewart et al.
NEUROLOGY (2001)
Practice parameter: Evidence-based guidelines for migraine headache (an evidence-based review) - Report of the Quality Standards Subcommittee of the American Academy of Neurology
SD Silberstein
NEUROLOGY (2000)
Acute migraine treatment outcome measures: a clinician's view
FD Sheftell et al.
CEPHALALGIA (2000)
分享论文
